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Background. Severe adverse events after treatment with ivermectin in individuals with high levels of Loa loa microfilariae in the 
blood preclude onchocerciasis elimination through community-directed treatment with ivermectin (CDTI) in Central Africa. We 
measured the cost of a community-based pilot using a test-and-not-treat (TaNT) strategy in the Soa health district in Cameroon.
Methods. Based on actual expenditures, we empirically estimated the economic cost of the Soa TaNT campaign, including fi-
nancial costs and opportunity costs that will likely be borne by control programs and stakeholders in the future. In addition to the 
empirical analyses, we estimated base-case, less intensive, and more intensive resource use scenarios to explore how costs might 
differ if TaNT were implemented programmatically.
Results. The total costs of US$283 938 divided by total population, people tested, and people treated with 42% coverage were 
US$4.0, US$9.2, and US$9.5, respectively. In programmatic implementation, these costs (base-case estimates with less and more in-
tensive scenarios) could be US$2.2 ($1.9–$3.6), US$5.2 ($4.5–$8.3), and US$5.4 ($4.6–$8.6), respectively.
Conclusions. TaNT clearly provides a safe strategy for large-scale ivermectin treatment and overcomes a major obstacle to 
the elimination of onchocerciasis in areas coendemic for Loa loa. Although it is more expensive than standard CDTI, costs vary 
depending on the setting, the implementation choices made by the institutions involved, and the community participation rate. 
Research on the required duration of TaNT is needed to improve the affordability assessment, and more experience is needed to un-
derstand how to implement TaNT optimally.
Keywords. onchocerciasis; Loa loa; cost analysis; point-of-care testing; disease elimination.
Community-directed treatment with ivermectin (CDTI) has 
been used since 1999 as the main strategy to combat oncho-
cerciasis in Africa [1, 2]. While generally considered safe, iver-
mectin has been associated with severe adverse events (SAEs) 
in individuals with high levels of circulating microfilariae (mf) 
of Loa loa (another filarial parasite endemic in Central Africa) 
[3, 4]. CDTI has been implemented in coendemic areas where 
the proportion of individuals with Onchocerca volvulus nodules 
exceeds 20% (hyperendemic and mesoendemic areas), albeit 
with enhanced adverse event (AE) surveillance. However, fear 
of SAEs has caused individuals in such areas to refuse treatment, 
leading to suboptimal drug coverage and continued O. volvulus 
transmission. Moreover, CDTI is not recommended in Loa-
coendemic areas where O.  volvulus is hypoendemic (nodule 
prevalence <20%), as the risk of SAEs is thought to outweigh 
the benefits of CDTI. This jeopardizes onchocerciasis elimina-
tion in Africa [5, 6].
A test-and-not-treat (TaNT) strategy using a smartphone-
based videomicroscope (LoaScope) enabled the safe imple-
mentation of ivermectin treatment in a pilot study in the Okola 
health district (HD) in Cameroon where all individuals ≥5 years 
of age [7, 8] were included. Of 16 259 tested individuals, only 
340 (2.1%) were excluded from ivermectin treatment because 
of microfilarial counts >20 000 mf/mL, whereas 15 522 (95.5%) 
were treated without the occurrence of SAEs [7]. A  second 
TaNT study in Soa HD also had no postivermectin SAEs and 
further demonstrated that TaNT could be performed by local 
health workers and community members under the supervi-
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this TaNT round in the Soa HD can be found in Supplementary 
Appendix 1.
Although TaNT is a promising strategy for onchocerciasis 
elimination in loiasis-coendemic areas, its implementation is 
expected to be costlier than that of CDTI. Consequently, there 
are affordability concerns at a wider scale. Thus, we measured 
the cost of community-based TaNT in the above-mentioned 
Soa pilot study [9]. In addition, we estimated the cost for 3 pro-
grammatic implementation scenarios (base-case, less intensive, 
and more intensive), to obtain a range of plausible estimates 
under different assumptions of resource use.
METHODS
General Approach
A microcosting approach [10] was used to empirically assess 
the cost of a community-based TaNT in the Soa HD [9]. The 
empirical costing study reflects the costs borne by the organ-
izations involved in implementing and executing the program 
in this specific pilot. A future program would likely be run by 
the Cameroonian Ministry of Health (MoH) in partnership 
with nongovernmental development organizations (NGDOs). 
We aimed to reflect this future situation in our cost calculations 
and therefore calculated the economic costs of the pilot, in-
cluding financial costs (explicit cash expenditures on project 
activities) and added relevant opportunity costs (resources that 
could be used in other projects, if not used in this one) [11]. 
We designed the protocol, data collection instruments, and cost 
calculation sheets following standard guidelines and reported 
input quantities and costs to maximize comparability with 
other studies and recently published mass drug administration 
(MDA) benchmarks [11, 12].
Study Area and Population
The Soa HD in Cameroon (Figure 1) is an ivermectin-naive dis-
trict that is hypoendemic for onchocerciasis and coendemic for 
loiasis [13]. It is located 17 km from Yaoundé (Cameroon’s cap-
ital) and is easily accessible. Soa HD consists of 6 health areas (3 
rural, 2 semiurban, 1 urban) and its population was estimated 
at 71 643 inhabitants, according to the census performed as part 
of the TaNT pilot.
Time Window
The census, testing/treating, and monitoring of SAEs in the 
TaNT round took place from September 2017 to February 2018. 
Costs were collected beginning with the preparation of the 
round in August 2017 until the last payments in March 2018.
Cost Calculation Components
The “supplies” category includes (but is not restricted to) fuel, 
car maintenance, food, transportation, office materials, field 
materials, and drugs to treat AEs. The “personnel” category 
includes per diems of community drug distributors (CDDs) 
and other staff, project staff salaries, and fringe costs for study 
personnel, when applicable. Overhead costs were not explic-
itly measured but were assumed to be 15% of direct costs, as 
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reported in the project budget. Supplementary Appendices 1 
and 2: Tables 1, 2, and 4) provide additional information. We 
excluded the following costs: ivermectin costs (as the drug 
was donated); bank tariffs; management/administrative costs 
incurred outside the country; costs incurred by households to 
be treated; opportunity cost of time spent by school staff; and 
opportunity costs of buildings used by MoH staff and of capital 
items purchased for previous projects.
Costs of LoaScopes and capillaries were provided in US dollars 
(US$); all other costs were reported in Central African francs 
(XAF) and converted to US$ using the US Treasury Reporting 
Rates of Exchange of 31 December 2017 (US$1 = XAF 568) [14].
Data Collection
Costs were based on actual payments or booked transfers col-
lected from all invoices and bank transactions provided by 
project managers. External MoH staff working in the project 
and CDDs were interviewed using structured questionnaires to 
obtain information about their time spent on the project and 
opportunity cost of their salaries. A  summary of the design, 
structure, and dissemination protocol for each questionnaire 
and English versions of these can be found in Supplementary 
Appendix 3: Table 6 and Questionnaires 1–3).
Data Entry, Cleaning, and Analysis
The invoices were analyzed and compared to the data pro-
vided by monthly financial reports and bank transactions for 
consistency and quality checks. The value of each invoice or 
bank transaction was labeled according to the input category, 
the health area in which the cost was incurred (using the label 
“district costs” if costs were not specific to any health area, but 
relative to the project as a whole), and the activity to which 
the cost could be attributed (advocacy, census, planning and 
budgeting, procurement, training, health education in the 
community and mobilization [HECM], delivery and distribu-
tion of interventions to target populations, AE surveillance and 
management, monitoring and evaluation, and general manage-
ment). Data from invoices and questionnaires were entered into 
a Microsoft Excel spreadsheet for further analysis. Overhead 
costs were added to the subtotal and the final result was divided 
by the project outputs.
Scenario Analysis
To assess the effect of different implementation strategies on the 
overall cost of TaNT, costs were calculated using 3 hypothetical 
alternative TaNT implementation scenarios: “base-case,” “less 
intensive resource use,” and “more intensive resource use.” The 
scenarios were designed based on the literature and our own 
expertise in conducting CDTI in Cameroon, using the same 
HD for context (eg, applying the same rural/urban distribution, 
same distances to the capital, same mode of delivery) [2, 15]. 
Table 1 describes the main differences between the scenarios 
and the pilot. See Supplementary Appendix 4: Tables 7–9) for a 
more detailed description.
Table 1. Summarized Description of Alternative Scenarios
Cost Category
Cost Scenario
Base-case Less Intensive Resource Use More Intensive Resource Use
Personnel
 Supervision and 
M&E
<< pilot 
Smaller teams and fewer days than pilot
<<< pilot 
Same team and fewer days than 
base-case
< pilot 
Bigger team and more days than base-case
 HECM < pilot (no sound cara) < pilot (no sound cara) < pilot (no sound cara)
 AE surveillance 
and management
Same as pilot << pilot (50% less than pilot) Same as pilot
 CDDs < pilot (CDDs only paid for training days) < pilot (CDDs only paid for 
training days)
>> pilot (CDDs were paid per diems for treatment 
days corresponding to the average income of an 
8-h workday (to account for income loss)
 Blood drawers 
and loascopists
> pilot (were paid a higher transport fee 
per field day, to account for more distant 
communities: based on responses of 
questionnaires)
> pilot (same as base-case) >> pilot (higher transport fees than base-case)
 School workers None None 100 workers
Supplies
 Fuel >  pilot (extra fuel allowance for MoH and 
NGDO cars)
> pilot (same as base-case) >> pilot (higher allowances than base-case)
 LoaScopes and 
capillaries
< pilot (assumed large-scale prices) < pilot (same as base-case) Same as pilot
 Other 
consumables
< pilot (30% less than pilot) < pilot (50% less than pilot) Same as pilot
Abbreviations: <, less than; <<, lesser than; <<<, much lesser than; >, more than; >>, much more than; AE, adverse events; CDD, community drug distributors; HECM, health education 
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RESULTS
The population size and numbers of individuals tested, treated, 
or excluded, as well as the occurrence of AEs, per health area 
are given in Table 2. Only 0.8% of the tested population was 
excluded from treatment. The overall coverage was relatively 
low (42%).
The costs of the pilot, disaggregated by programmatic activity, 
are presented in Table 3. The costliest activities were related to 
the actual delivery of the intervention (31%) and HECM (11%), 
although general management costs (not related to a specific 
activity) also formed a large part of the total costs (19%). The 
supplies input categories that were responsible for the highest 
shares of the total costs (from highest to lowest), are capillaries 
and information, education, and communication materials 
leading with 12% and 10% of the total pilot costs, respec-
tively (Supplementary Appendix 2: Table 3). Supplementary 
Appendix 5: Table 10 shows volumes and prices of supplies per 
input category.
The majority of the personnel costs were not related to a spe-
cific activity but to actions related to the implementation of the 
round as a whole. The same holds true for district and health 
area level MoH personnel. The main costs of all other categories 
were related to the delivery of the intervention (Supplementary 
Appendix 2: Table 5).
The total cost for the entire pilot was US$283  938 (Table 
4), with a cost per person treated of US$9.5. The cost per 
person treated was reduced to US$5.4 for the base-case and to 
US$4.6 and US$8.6 for the less and more intensive scenarios, 
respectively.
The absolute costs of the Soa pilot and each of the implemen-
tation scenarios disaggregated by programmatic activity, as well 
as the percentages of each activity, are given in Figure 2. The 
empirical study was more expensive than the scenarios, mainly 
due to the census, HECM, general management costs (for in-
stance car maintenance and field materials), and the costs of 
LoaScopes and capillaries. Costs of delivering the intervention 
formed the largest share of the total costs, mainly due to the 
costs of capillaries, field material, and per diems, which showed 
a reduction in the base-case and less intensive scenarios mostly 
due to less supervision and less expensive materials. Costs 
increased considerably in the more intensive scenario, due to 
the payment of higher per diems to CDDs to account for in-
come loss. Even though general management costs were also 
reduced by less expensive materials in the scenarios, the per-
centage of the total costs did not change much. Costs of HECM 
were lower in the scenarios because of the exclusion of the costs 
of the megaphone-equipped car and the reduction of prices of 
materials.
DISCUSSION
This study provides both empirical cost estimates of a pilot and 
projected costs based on scenario analyses using the new TaNT 
strategy in regions coendemic for O. volvulus and L. loa. Based 
on actual expenditure during the pilot, this strategy cost US$4.0 
per person in the population, US$9.2 for each person tested, and 
US$9.5 for each person treated. In the alternative implementa-
tion scenarios, these costs (shown as base-case estimates with 
less and more intensive scenarios) were estimated to be US$2.2 
($1.9–$3.6), US$5.2 ($4.5–$8.3), and US$5.4 ($4.6–$8.6), as-
suming that population participation remained unchanged.
Several limitations apply to the internal validity of our study. 
Despite the careful collection of available data from invoices, 
bank transfers, and questionnaires, we had to adapt to the 
system usually used by financial managers of the implementing 
institution, without explicit reporting of the cost of previously 
acquired capital items or building rental. Using a retrospective 
questionnaire investigating opportunity costs of MoH staff was 
also not ideal, as it allows recall bias. Opportunity costs of time 
spent by school staff when helping during the treatment phase 
and of vehicles and furniture acquired for other projects were 
not included in this study, leading to a slight underestimation 
of the costs of the pilot. These limitations should be addressed 














Ting Melen (r) 1967 1697 1644 1585 16 43 7 81
Koulou (r) 1534 1342 1035 975 38 22 18 64
Ngali 2 (r) 1869 1594 1017 963 36 18 19 52
Ebang (su) 23 209 19 906 11 412 10 987 53 372 47 47
Ntouessong (su) 10 162 8618 3602 3473 44 85 25 34
Soa (u) 32 902 29 524 12 098 11 765 58 275 68 36
Total 71 643 62 681 30 808 29 748 245 815 184 42
Abbreviations: AE, adverse event; mf, microfilariae; r, rural; su, semiurban; u, urban.
aPregnant and breastfeeding women, individuals suffering from chronic disease.
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in future studies to increase the accuracy of cost estimates and 
enable policymakers to anticipate their costs more reliably. This 
would also allow economic costs to be presented separated from 
financial costs.
Because we measured costs in a study setting, alongside a 
pilot implementation of community-based TaNT, our results 
may not be fully representative of a programmatic setting, lim-
iting the external validity. Some costs may have been higher 
than expected under programmatic implementation (eg, all 
personnel received intensive training and supervision and 
CDDs received payment). Furthermore, best implementation 
practice still remains to be determined, and future programs 
may be implemented somewhat differently. The programmatic 
operationalization scenarios were designed to address the ex-
ternal validity limitations. They still do not cover all possible 
variations in implementation choices. We built the base-case 
scenario aiming to reflect Cameroonian reality as much as pos-
sible. As shown in the scenario analyses, costs heavily depend 
on implementation choices, and cost-savings compared to the 
pilot can be achieved through reductions in supervisory per-
sonnel, health education and sensitization, surveillance and 
management of AEs, and purchase prices of the LoaScopes 
and capillaries. The last 2 categories can be further reduced 
by implementing NGDOs/MoH if external funding agencies 
Table 3. Total Costs of Pilot per Activity (US Dollars)
Program Activity Supplies Personnel Total Percentage of Total Pilot Costs
1. Advocacy 6020 843 6864 2%
2. Census 741 18 975 19 715 7%
3. Planning and budgeting 100 8071 8170 3%
4. Procurement 30 9 39 0.01%
5. Training 2537 13 542 16 078 6%
6. HECM 21 442 8979 30 421 11%
7. Delivery intervention 46 527 42 137 90 115 31%
8. AE surveillance and management 2048 10 253 12 300 4%
9. M&E 107 11 606 11 712 4%
10. General managementa 18 280 34 613 52 892 19%
Subtotal activities 97 830 149 027 248 308 87%
Overhead costs b b 37 253b 13%
Total 112 504 171 381 283 885 100%
Abbreviations: AE, adverse event; HECM, health education in the community and mobilization; M&E, monitoring and evaluation.
aIncludes all inputs related to the project as a whole and that could not be attributed to a specific activity (eg, electricity, some office supplies, communication, some of the fuel and car 
maintenance costs).
bCalculated as 15% of the activities subtotal.
Table 4. Total Costs per Round and per Program Output (US Dollars): Pilot and Alternative Scenarios
Health Area and Scenario




Cost per Person 
Censused
Cost per Person 
Tested





Empirical cost estimates by health area
 Ting Melen (r) 17 770 1967 9.0 10.8 11.2a 81b
 Koulou (r) 14 994 1534 9.8 14.5 15.4a 64b
 Ngali 2 (r) 16 161 1869 8.6 15.9 16.8a 52b
 Ebang (su) 90 425 23 209 3.9 7.9 8.2 47c
 Ntouessong (su) 41 163 10 162 4.1 11.4 11.9 34c
 Soa (u) 103 425 32 902 3.1 8.5 8.8 36c
 Total costs of the TaNT pilot 283 938 71 643 4.0 9.2 9.5 42
Alternative implementation scenarios
 Base-case 159 349 71 643 2.2 5.2 5.4 42
 Less intensive 137 289 71 643 1.9 4.5 4.6 42
 More intensive 255 850 71 643 3.6 8.3 8.6 42
Abbreviations: r, rural; su, semiurban; TaNT, test and not treat; u, urban.
aRural areas had a higher cost per person treated due to more supervisory personnel (they were the first areas to participate in the pilot), more fuel costs (increased distance from the 
capital), and additional testing/treating at schools.
bRural areas had higher coverage because people are at home or work close to home and can be reached more easily by community drug distributors during the sensitization phase and 
because people are available during sampling hours (sampling needs to be done during regular school/work hours [between 10:00 am and 4:00 pm] due to the diurnal periodicity of Loa loa 
microfilaremia).
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opt to donate these supplies to countries choosing to imple-
ment the TaNT strategy, as already done with the donation of 
ivermectin.
Overall study coverage was relatively low, particularly in the 
semiurban and urban areas. Higher coverage is essential to on-
chocerciasis elimination. Achieving high coverage in urban 
areas is a known problem, even in standard CDTI, due to lack of 
trust in public programs, migrant populations, and disorganized 
poor urban settlements [16, 17]. Yet, it may be even more diffi-
cult to achieve in TaNT programs, as blood sampling needs to 
be done during regular school/work hours, requires the involve-
ment of additional people (blood drawers and “loascopists”), 
and is best done with a mobile station rather than house-to-
house. Additional measures are needed to increase coverage, 
including continuous and improved health education/mobiliza-
tion and alternative ways to offer testing and treatment, such as 
mobile stations at schools and in commercial/industrial areas. 
However, because it is difficult to predict the cost and impact of 
these measures on coverage, we have not considered increases 
in coverage in our implementation scenarios. Although there 
will be some economies of scale (fixed costs divided over a 
larger population), other costs are likely to increase with the 
number of people covered (eg, personnel costs for delivering 
the intervention), resulting in a higher cost per person.
Our estimates, derived from a community-based single 
study, are not directly transferable to other settings due to many 
factors, such as variations in local prices, organization and 
availability of healthcare, and geographic characteristics such as 
remoteness, accessibility, and level of “urbanness” [18, 19].
To eliminate onchocerciasis, treatment would have to be re-
peated yearly (or more frequently) for many years with suffi-
cient treatment coverage (ie, 80% of the eligible population per 
World Health Organization guidance) [20]. The costs of future 
rounds are likely to be significantly lower than the initial round 
for a number of reasons, including the absence of startup costs, 
shared fixed costs (over multiple rounds within a given year), 
more efficient implementation (from the experience and struc-
ture provided by the first round), lower intensity of HECM 
(communities would already be aware of the strategy), and less 
MoH advocacy and AE surveillance (since fewer cases would 
need to be followed). Further, as L.  loa microfilarial densities 
remain low after treatment for at least 18 months, people proven 
to be treated in the previous round (using reidentification 
methods) would not need to be retested [21]. Capillary and 
LoaScope costs would only remain for the individuals not pre-
viously tested and treated, making costs much more compa-
rable to those of standard CDTI.
To date, there are no studies of the costs of alternative 
strategies of measuring L.  loa microfilarial densities before 
treating for onchocerciasis to which we could compare our 
results. We cannot directly estimate the difference in costs 
between TaNT and CDTI without empirical comparisons, as 
it is impossible to disentangle costs of treatment from those 
of testing in the TaNT strategy. A  unit cost benchmarking 
study by Fitzpatrick et  al [11] showed that the unit cost of 
mass drug administration is highly variable, depending very 
much on the use of volunteers and economies of scale. This 
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any previously published figures. A  web-based tool [11] that 
provides unit cost benchmarks for different settings allowed us 
to estimate the expected cost of a first round of standard CDTI 
in Soa, using the corresponding population and characteristics 
of the area (which the tool allows), and the resulting cost esti-
mate was US$18.3 (95% confidence interval [CI], $6.9–$35.6) 
per person treated using paid community health workers. 
The observed cost of TaNT for the pilot and more intensive 
scenario are closer to the lower end of the range despite the 
cost of testing. The benchmark unit cost of standard CDTI is 
considerably lower when implemented by unpaid community 
volunteers, US$3.9 (95% CI, $2.2–$5.7), and the cost of our 
base-case and low-intensity implementation scenario comes 
quite close to this. Details on the use of the benchmark tool are 
provided in Supplementary Appendix 6.
Through TaNT, community treatment with ivermectin can 
be expanded into the many areas in central Africa that are 
hypoendemic for onchocerciasis and coendemic for loiasis, 
where standard CDTI cannot be applied for safety reasons. 
Implementing treatment in these regions is crucial for the 
continent-wide elimination of onchocerciasis, with associated 
health and socioeconomic benefits estimated at more than 
US$6 billion [22]. The populations concerned will not only ben-
efit from the control and potential elimination of onchocerciasis 
but—as ivermectin is a broad-spectrum anthelmintic drug—
also from the effects of treatment of other parasitic diseases in-
cluding scabies and soil-transmitted helminthiases.
CONCLUSIONS
Costs of TaNT are higher than costs of standard CDTI. How 
much higher will depend on how subsequent treatment rounds 
will be implemented and the required program duration. The 
duration will not be much longer than in Loa-free areas if the 
coverage is sufficiently high and the proportion of the popu-
lation excluded from treatment (because of high-density loi-
asis) is as low as observed in Soa and Okola (1% on average). 
The effect of excluding people from treatment may be more 
important where the proportion of people excluded due to lo-
iasis is higher, but this can be mitigated by offering alternative 
treatment for onchocerciasis, such as a course of doxycycline. 
Although we did not assess the costs associated with such treat-
ment, these should be weighed against the impact on program 
duration and success.
Even though TaNT is undoubtedly more expensive than 
MDA, onchocerciasis elimination will not be reached without 
a strategy that can be safely used in areas coendemic for L. loa. 
Our empirical study shows that TaNT using LoaScopes remains 
affordable, given the enormous potential economic benefits 
of reaching elimination of onchocerciasis in Cameroon and 
in other countries where L. loa is coendemic with O. volvulus. 
Various implementation scenarios show that costs could be 
further reduced. Future studies in this field are needed to inves-
tigate the costs of a programmatic implementation.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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